A citation-based method for searching scientific literature

Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
Times Cited: 1113



Hyoung Kim, Erin George, Ryan Ragland, Stavros Rafail, Rugang Zhang, Clemens Krepler, Mark Morgan, Meenhard Herlyn, Eric Brown, Fiona Simpkins. Clin Cancer Res 2017
Times Cited: 152




List of shared articles



Times cited

Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer.
Ke Shen, Li Yang, Fei-Yan Li, Feng Zhang, Lei-Lei Ding, Jing Yang, Jie Lu, Nan-Nan Wang, Yan Wang. Curr Drug Targets 2022
2

Therapeutic Targeting of DNA Damage Response in Cancer.
Wonyoung Choi, Eun Sook Lee. Int J Mol Sci 2022
3

DNA repair defects in cancer and therapeutic opportunities.
Jessica L Hopkins, Li Lan, Lee Zou. Genes Dev 2022
0


The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
Vinayak Palve, Claire E Knezevic, Daniel S Bejan, Yunting Luo, Xueli Li, Silvia Novakova, Eric A Welsh, Bin Fang, Fumi Kinose, Eric B Haura,[...]. Cell Chem Biol 2022
3

Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer.
Jyotirindra Maity, Sachi Horibata, Grant Zurcher, Jung-Min Lee. Cancers (Basel) 2022
0

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use.
Rachel Abbotts, Anna J Dellomo, Feyruz V Rassool. Cancers (Basel) 2022
0

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W G Wijnhoven, Adina M Hughes, Joe Gerrard, Gemma N Jones, Hannah Bargh-Dawson, Elaine Brown, Lucy A Young,[...]. Cancer Res 2022
0